A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

830

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

BIOLOGICAL: Rilvegostomig
BIOLOGICAL: Pembrolizumab

Sponsor

AstraZeneca